GGrantIndex
Sort

40,608 grants matching prostate cancer

CANCER CENTER SUPPORT GRANT

$705,954
Wayne State University · P30 · FY2002 · CA

Health Disparities and CVD: Admixture Mapping in the Jackson Heart Study

$705,882
James Graham Wilson · University Of Mississippi Med Ctr · R01 · FY2009 · HL

Georgia CaRes

$705,799
Sharad A. Ghamande · Augusta University · UG1 · FY2017 · CA

Community Outreach and Engagement (COE)

$705,778
Roshan Bastani · University Of California Los Angeles · P30 · FY2025 · CA

Enhancing ARIC Infrastructure to Yield a New Cancer Epidemiology Cohort

$705,735
Elizabeth A. Platz · Johns Hopkins University · U01 · FY2015 · CA

Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study

$705,569
Demetrius Albanes · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA

Discovery and characterization of clinically actionable germline mutations in DNA damage repair (DDR) pathway genes in lung cancer

$705,297
Semanti Mukherjee · Sloan-Kettering Inst Can Research · R37 · FY2023 · CA

Southeast Michigan Community Network Program

$705,220
Terrance L. Albrecht · Wayne State University · U54 · FY2013 · CA

Transgenic Core Facility

$705,137
Deborah Swing · Division Of Basic Sciences - Nci · ZIC · FY2009 · CA

Minority Based Community Clinical Oncology Program

$705,000
David J Peace · University Of Illinois At Chicago · U10 · FY2007 · CA

Macrocycle inhibition of beta-catenin mediated transcription in prostate cancer

$704,918
Susan K. Logan · New York University School Of Medicine · R01 · FY2024 · CA

Family RESPOND: Defining the Genetic Basis of Prostate Cancer Risk in African American Families

$704,882
Christopher Alan Haiman · University Of Southern California · R01 · FY2025 · CA

Quantitative MRI to automatically delineate intraprostatic tumor for radiation therapy

$704,563
Kun Qing · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA

Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate

$704,422
Lisa Bodei · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA

New Instrumentation and Techniques for Hyperpolarized Metabolic and Perfusion MRI

$704,365
Daniel B Vigneron · University Of California, San Francisco · R01 · FY2013 · EB

Perfluoroalkyl Substances (PFASs) and Liver Cancer Risk in the United States

$704,354
Xuehong Zhang · Brigham And Women'S Hospital · U01 · FY2023 · CA

ROLE OF PEPC, A CIRCULAR RNA ENCODED PROTEIN, IN CASTRATION-RESISTANT PROSTATE CANCER

$704,321
Regents Of The University Of Minnesota · · FY2017 · Department of the Army

[PQC-3] A Metabolic Pathway Activation Marker for Prostate Cancer Prognosis

$704,248
David J Beebe · University Of Wisconsin-Madison · R01 · FY2016 · CA

Biological Studies

$704,174
Brian E Henderson · University Of Southern California · U19 · FY2013 · CA

Exploring PSMA Biology in Tumor neovasculature

$704,122
Jan Grimm · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA

A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer

$704,036
Lorna Rodriguez-Rodriguez · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA

COMBINING CAR T CELLS WITH BLOCKADE OF TUMOR- INDUCED IMMUNOSUPPRESSION TO TARGET METASTATIC PROSTATE CANCER

$704,000
University Of Southern California · · FY2021 · Defense Health Agency

Cancer Center Support Grant (Comprehensive)

$704,000
Lawrence Corey · Fred Hutchinson Cancer Research Center · P30 · FY2011 · CA

ERADICATING METASTATIC PROSTATE CANCER THROUGH THE SYSTEMATIC IDENTIFICATION OF SYNERGISTIC DRUG COMBINATIONS

$703,705
The Johns Hopkins University · · FY2018 · Department of the Army

A Systems Biology Approach to the Development of Cancer Biomarkers

$703,683
Arul M Chinnaiyan · University Of Michigan At Ann Arbor · U01 · FY2010 · CA